trial

Galantamine for Cognition in People With Schizophrenia

NCTId NCT00320736
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 20
Sponsored by North Suffolk Mental Health Association
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
20
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-01
Primary completion
—
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Galantamine

Sponsors

North Suffolk Mental Health AssociationLead Sponsor
Janssen, L.P. - Investigator Initiated Studies ProgramCollaborator

Investigators

1
A. Eden Evins, MD, MPHPrincipal Investigator

Sites

1 total
Boston, United States

Facts & assertions

3 sourced
Enrollment
20
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Galantamine
drug
lead_sponsor
North Suffolk Mental Health Association
company
collaborator
Janssen, L.P. - Investigator Initiated Studies Program
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
A. Eden Evins, MD, MPH
person